Recommendations from the European LeukemiaNet for the Management of CML4
MMR indicates BCR/ABL1 <0.1%; CCA/Ph+, clonal chromosomal abnormalities in Ph+ cells; and CCA/Ph−, clonal chromosomal abnormalities in Ph− cells.
* Loss of MMR should be confirmed in 2 consecutive quantitative RT-PCR tests, of which one has a BCR/ABL1 transcripts level >1%.
Monitoring is performed by metaphase cytogenetics on bone marrow aspirate sample and/or by quantitative RT-PCR for BCR/ABL1 transcript levels on blood samples.